Successful Pregnancy Outcome in a Patient Treated with Pembrolizumab and Exposed to Fluoro-Deoxyglucose (18F-FDG) PET/CT: Case Report and Review of Literature
Abstract
:1. Introduction
2. Case Report
- -
- Treatment with pembrolizumab from July 2022 to December 2022 (six cycles of 200 mg) with a possible sixth cycle occurring in the periconceptional period.
- -
- Treatment with pembrolizumab, 200 mg in February, March, April, May during the first and second trimester.
- -
- 18F-FDG PET/CT on 18 January 2023, first trimester.
3. Discussion
- -
- A 25-year-old patient with classical Hodgkin’s lymphoma. Initially treated with chemotherapy and autologous stem cell transplantation, followed by 21 cycles of pembrolizumab. Two years after treatment, an unexpected pregnancy occurred, resulting in a healthy live birth without maternal or fetal complications [29].
- -
- A 40-year-old nulliparous patient with advanced-stage melanoma diagnosed in the first trimester. Despite maternal and fetal risks, the patient decided to continue the pregnancy and was treated with pembrolizumab from 21 to 27 weeks of gestation. A cesarean section was performed at 28 weeks, delivering a newborn without complications. Maternal outcomes, however, showed disease progression despite treatment [30].
- -
- A 35-year-old patient with gastric cancer, treated with neoadjuvant chemotherapy and subsequent surgery. During follow-up, metastases were detected, and the patient underwent radiotherapy followed by immunotherapy. During these treatments, a pregnancy was diagnosed, and the patient decided to continue it. Fetal growth restriction and dilated fetal bowel led to cesarean delivery at 35 weeks. Necrotizing enterocolitis occurred, requiring surgical resection, while the patient continued pembrolizumab treatment and achieved positive responses [31].
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Javitt, M.C. Cancer in pregnancy: Overview and epidemiology. Abdom. Radiol. 2023, 48, 1559–1563. [Google Scholar] [CrossRef] [PubMed]
- Shandley, L.M.; Kipling, L.M.; Spencer, J.B.; Morof, D.; Mertens, A.C.; Howards, P.P. Factors Associated with Unplanned Pregnancy Among Cancer Survivors. J. Women’s Health 2022, 31, 665–674. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Froesch, P.; Belisario-Filho, V.; Zucca, E. Hodgkin and non-Hodgkin lymphomas during pregnancy. In Cancer and Pregnancy; Recent Results in Cancer Research; Springer: Berlin/Heidelberg, Germany, 2008; Volume 178, pp. 111–121. [Google Scholar] [CrossRef] [PubMed]
- Lishner, M.; Avivi, I.; Apperley, J.F.; Dierickx, D.; Evens, A.M.; Fumagalli, M.; Nulman, I.; Oduncu, F.S.; Peccatori, F.A.; Robinson, S.; et al. Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting. J. Clin. Oncol. 2016, 34, 501–508. [Google Scholar] [CrossRef] [PubMed]
- Eichenauer, D.A.; Aleman, B.M.P.; André, M.; Federico, M.; Hutchings, M.; Illidge, T.; Engert, A.; Ladetto, M.; ESMO Guidelines Committee. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2018, 29 (Suppl. S4), iv19–iv29. [Google Scholar] [CrossRef] [PubMed]
- Altini, C.; Niccoli Asabella, A.; De Luca, R.; Fanelli, M.; Caliandro, C.; Quartuccio, N.; Rubini, D.; Cistaro, A.; Montemurro, S.; Rubini, G. Comparison of 18F-FDG PET/CT methods of analysis for predicting response to neoadjuvant chemoradiation therapy in patients with locally advanced low rectal cancer. Abdom. Imaging 2015, 40, 1190–1202. [Google Scholar] [CrossRef] [PubMed]
- Burton, C.S.; Frey, K.; Fahey, F.; Kaminski, M.S.; Brown, R.K.J.; Pohlen, J.M.; Shulkin, B.L. Fetal Dose from PET and CT in Pregnant Patients. J. Nucl. Med. 2023, 64, 312–319. [Google Scholar] [CrossRef] [PubMed]
- Al Mansour, L.; Tylski, P.; Chene, G.; Plaisant, F.; Janier, M.; Bolze, P.A.; You, B.; Defez, D.; Tordo, J.; Flaus, A. Estimated Fetal Radiation Dose From 18 F-FDG PET/CT During the Second and Third Trimesters of Pregnancy. Clin. Nucl. Med. 2024, 49, 605–609. [Google Scholar] [CrossRef] [PubMed]
- Chen, R.; Zinzani, P.L.; Fanale, M.A.; Armand, P.; Johnson, N.A.; Brice, P.; Radford, J.; Ribrag, V.; Molin, D.; Vassilakopoulos, T.P.; et al. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J. Clin. Oncol. 2017, 35, 2125–2132. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Topalian, S.L.; Taube, J.M.; Anders, R.A.; Pardoll, D.M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 2016, 16, 275–287. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Habicht, A.; Dada, S.; Jurewicz, M.; Fife, B.T.; Yagita, H.; Azuma, M.; Sayegh, M.H.; Guleria, I. A link between PDL1 and T regulatory cells in fetomaternal tolerance. J. Immunol. 2007, 179, 5211–5219. [Google Scholar] [CrossRef] [PubMed]
- Xu, W.; Moor, R.J.; Walpole, E.T.; Atkinson, V.G. Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: Case report and review of the literature. Melanoma Res. 2019, 29, 333–337. [Google Scholar] [CrossRef] [PubMed]
- De Robertis, V.; Calì, G.; Corbella, P.; Formigoni, C.; Iuculano, A.; Nonino, F.; Pasquini, L.; Prefumo, F.; Sciarrone, A.; Stampalija, T.; et al. Referral scan for congenital anomalies: Time to agree on indications. Ultrasound Obstet. Gynecol. 2022, 60, 597–603. [Google Scholar] [CrossRef] [PubMed]
- Il Follow-Up del Neonato Pretermine. I Primi Sei Anni di Vita; iDea Cpa Editore: Rome, Italy, 2022; ISBN 978-88-946318-7-6. Available online: https://www.sin-neonatologia.it/il-follow-up-del-neonato-pretermine/ (accessed on 1 December 2024).
- Pentheroudakis, G.; Pavlidis, N. Cancer and pregnancy: Poena magna, not anymore. Eur. J. Cancer 2006, 42, 126–140. [Google Scholar] [CrossRef] [PubMed]
- Weibull, C.E.; Eloranta, S.; Smedby, K.E.; Björkholm, M.; Kristinsson, S.Y.; Johansson, A.L.; Dickman, P.W.; Glimelius, I. Pregnancy and the Risk of Relapse in Patients Diagnosed With Hodgkin Lymphoma. J. Clin. Oncol. 2016, 34, 337–344. [Google Scholar] [CrossRef] [PubMed]
- Cardonick, E.; Iacobucci, A. Use of chemotherapy during human pregnancy. Lancet Oncol. 2004, 5, 283–291. [Google Scholar] [CrossRef] [PubMed]
- Esposito, S.; Tenconi, R.; Preti, V.; Groppali, E.; Principi, N. Chemotherapy against cancer during pregnancy: A systematic review on neonatal outcomes. Medicine 2016, 95, e4899. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Vandenbroucke, T.; Verheecke, M.; Fumagalli, M.; Lok, C.; Amant, F. Effects of cancer treatment during pregnancy on fetal and child development. Lancet Child Adolesc. Health 2017, 1, 302–310. [Google Scholar] [CrossRef] [PubMed]
- Vaddepally, R.K.; Kharel, P.; Pandey, R.; Garje, R.; Chandra, A.B. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers 2020, 12, 738. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Robert, C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat. Commun. 2020, 11, 3801. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Geraud, A.; Gougis, P.; Vozy, A.; Anquetil, C.; Allenbach, Y.; Romano, E.; Funck-Brentano, E.; Moslehi, J.J.; Johnson, D.B.; Salem, J.E. Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance. Annu. Rev. Pharmacol. Toxicol. 2021, 61, 85–112. [Google Scholar] [CrossRef] [PubMed]
- Than, N.G.; Hahn, S.; Rossi, S.W.; Szekeres-Bartho, J. Editorial: Fetal-Maternal Immune Interactions in Pregnancy. Front. Immunol. 2019, 10, 2729. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- D’Addio, F.; Riella, L.V.; Mfarrej, B.G.; Chabtini, L.; Adams, L.T.; Yeung, M.; Yagita, H.; Azuma, M.; Sayegh, M.H.; Guleria, I. The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. J. Immunol. 2011, 187, 4530–4541. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Guleria, I.; Khosroshahi, A.; Ansari, M.J.; Habicht, A.; Azuma, M.; Yagita, H.; Noelle, R.J.; Coyle, A.; Mellor, A.L.; Khoury, S.J.; et al. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J. Exp. Med. 2005, 202, 231–237. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Borgers, J.S.W.; Heimovaara, J.H.; Cardonick, E.; Dierickx, D.; Lambertini, M.; Haanen, J.B.A.G.; Amant, F. Immunotherapy for cancer treatment during pregnancy. Lancet Oncol. 2021, 22, e550–e561. [Google Scholar] [CrossRef] [PubMed]
- Flynn, J.P.; Gerriets, V. Pembrolizumab. In StatPearls [Internet]; StatPearls Publishing: Treasure Island, FL, USA, 2023. [Google Scholar] [PubMed]
- Kwok, G.; Yau, T.C.; Chiu, J.W.; Tse, E.; Kwong, Y.L. Pembrolizumab (Keytruda). Hum. Vaccines Immunother. 2016, 12, 2777–2789. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Le-Nguyen, A.; Rys, R.N.; Petrogiannis-Haliotis, T.; Johnson, N.A. Successful pregnancy and fetal outcome following previous treatment with pembrolizumab for relapsed Hodgkin’s lymphoma. Cancer Rep. 2022, 5, e1432. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Anami, Y.; Minami, S.; Kumegawa, A.; Matsukawa, H.; Nishioka, K.; Noguchi, T.; Iwahashi, N.; Mizoguchi, M.; Nanjo, S.; Ota, N.; et al. Malignant melanoma treated with pembrolizumab during pregnancy: A case report and review of the literature. Mol. Clin. Oncol. 2021, 15, 242. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Piemonti, L.; Vettor, L.; Contro, E. A Case Report of Metastatic Gastric Cancer Treated with Pembrolizumab during Pregnancy. Fetal Diagn. Ther. 2024, 51, 493–499. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Andrikopoulou, A.; Korakiti, A.M.; Apostolidou, K.; Dimopoulos, M.A.; Zagouri, F. Immune checkpoint inhibitor administration during pregnancy: A case series. ESMO Open 2021, 6, 100262. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Gougis, P.; Hamy, A.S.; Jochum, F.; Bihan, K.; Carbonnel, M.; Salem, J.E.; Dumas, E.; Kabirian, R.; Grandal, B.; Barraud, S.; et al. Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and Newborns. JAMA Netw. Open 2024, 7, e245625. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
Burton et al. [7] | Al Mansour et al. [8] | Our Case | |
---|---|---|---|
N° of pregnancy | 9 | 18 | 1 |
Fetal-self dose | 1.2 to 8.2 mGy | 5.7–15.8 to 7.9–16.6 mGy (*) 5.1–11.6 to 6.1–10.7 mGy (°) | 11 mGy |
Patients | Gestational Age (Week) | SSDE Range (mGy) | 18F-FDG Fetal Self-Dose Range (mGy) | 18F-FDG Fetal Total Dose Range (mGy) | SSDE + 18F-FDG Fetal Self-Dose Range (mGy) |
---|---|---|---|---|---|
9 | From 12 to 36 | 1.0–6.9 | 0.0017–2.18 | 0.0034–2.35 | 1.2–8.2 |
Patients | Gestational Age (Weeks) | Average Patient Weight (kg) | Estimated Fetal Self-Dose CT-Expo Method (mGy) * | Estimated Fetal Self-Dose Virtual Dose (mGy) * | Estimated Fetal Self-Dose CT-Expo Method (mGy) ° | Estimated Fetal Self-Dose Virtual Dose (mGy) ° | Adverse Fetal Outcomes |
---|---|---|---|---|---|---|---|
18 | From 16 to 33 | 71.2 | 5.7–15.8 | 5.1–11.6 | 7.9–16.6 | 6.1–10.7 | / |
Indication | Cycles | Dose | Pregnancy Timing | Delivery | GA at Delivery | Maternal Outcome | Adverse Fetal Outcome | Neonatal Weight (g) | Percentile Weight | Apgar Scores | |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | Classical Hodgkin Lymphoma | 21 | ? | 2 years after treatment | VD | ? | R | / | 3100 | ? | 8–9 |
2 | Advanced Malignant Melanoma | 3 | 200 mg * | 21–27 weeks of gestation | CS | 28 weeks | PD | / | 1291 | >90° | 7–8 |
3 | Gastric Carcinoma | ? | 200 mg * | Treatment during pregnancy 2 years after treatment | CS | 35 weeks | PR | NEC | 1685 | <10° | 9–10 |
4 | Classical Hodgkin Lymphoma | 10 | 200 mg * | During pregnancy | VD | 37 weeks 5 days | PD | / | 2650 | <10° | 8–9 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mastricci, A.L.; Sorrentino, F.; Giansiracusa, E.; Zanzarelli, E.; De Lucia, G.S.; Fesce, V.F.; Nappi, L.; Vasciaveo, L. Successful Pregnancy Outcome in a Patient Treated with Pembrolizumab and Exposed to Fluoro-Deoxyglucose (18F-FDG) PET/CT: Case Report and Review of Literature. Biomedicines 2025, 13, 140. https://doi.org/10.3390/biomedicines13010140
Mastricci AL, Sorrentino F, Giansiracusa E, Zanzarelli E, De Lucia GS, Fesce VF, Nappi L, Vasciaveo L. Successful Pregnancy Outcome in a Patient Treated with Pembrolizumab and Exposed to Fluoro-Deoxyglucose (18F-FDG) PET/CT: Case Report and Review of Literature. Biomedicines. 2025; 13(1):140. https://doi.org/10.3390/biomedicines13010140
Chicago/Turabian StyleMastricci, Anna Lucia, Felice Sorrentino, Elisa Giansiracusa, Erika Zanzarelli, Graziana Silvana De Lucia, Vincenza Fernanda Fesce, Luigi Nappi, and Lorenzo Vasciaveo. 2025. "Successful Pregnancy Outcome in a Patient Treated with Pembrolizumab and Exposed to Fluoro-Deoxyglucose (18F-FDG) PET/CT: Case Report and Review of Literature" Biomedicines 13, no. 1: 140. https://doi.org/10.3390/biomedicines13010140
APA StyleMastricci, A. L., Sorrentino, F., Giansiracusa, E., Zanzarelli, E., De Lucia, G. S., Fesce, V. F., Nappi, L., & Vasciaveo, L. (2025). Successful Pregnancy Outcome in a Patient Treated with Pembrolizumab and Exposed to Fluoro-Deoxyglucose (18F-FDG) PET/CT: Case Report and Review of Literature. Biomedicines, 13(1), 140. https://doi.org/10.3390/biomedicines13010140